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Abstract
Diphtheria toxin (DT), Pseudomonas aeruginosa Exotoxin A (ETA) and cholix toxin from Vibrio cholerae share the same
mechanism of toxicity; these enzymes ADP-rybosylate elongation factor-2 (EF-2) on a modified histidine residue called
diphthamide, leading to a block in protein synthesis. Mutant Chinese hamster ovary cells that are defective in the formation
of diphthamide have no distinct phenotype except their resistance to DT and ETA. These observations led us to predict that
a strategy that prevents the formation of diphthamide to confer DT and ETA resistance is likely to be safe. It is well
documented that Dph1 and Dph2 are involved in the first biochemical step of diphthamide formation and that these two
proteins interact with each other. We hypothesized that we could block diphthamide formation with a dominant negative
mutant of either Dph1 or Dph2. We report in this study the first cellular-targeted strategy that protects against DT and ETA
toxicity. We have generated Dph2(C-), a dominant-negative mutant of Dph2, that could block very efficiently the formation
of diphthamide. Cells expressing Dph2(C-) were 1000-fold more resistant to DT than parental cells, and a similar protection
against Pseudomonas exotoxin A was also obtained. The targeting of a cellular component with this approach should have a
reduced risk of generating resistance as it is commonly seen with antibiotic treatments.
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Introduction
Diphtheria toxin (DT) and Pseudomonas aeruginosa exotoxin A
(ETA) are two bacterial A-B toxins that share the same mechanism
of toxicity. These toxins are characterized by a B moiety that
recognizes the cell surface receptor but that also plays a role in the
translocation of the toxin into the cytosol, and an A moiety that
contains the catalytic activity of the toxin. After binding to its
receptor and endocytosis, the A subunit of DT enters the cytosol
from the acidic endosomes and the one from ETA is released from
the endoplasmic reticulum. The A subunit can then inactivate the
elongation factor-2 (EF-2) by adenosine diphosphate (ADP)-
ribosylating a modified histidine residue called diphthamide
leading to cell death by blocking protein translation [1,2]. More
recently, it was reported that cholix toxin from Vibrio cholerae has
also a similar ADP-ribosylating activity on EF-2 [3].
P. aeruginosa is a Gram-negative bacillus ubiquitously present in
the environment and, according to the Central for Disease
Control, it is the fourth most commonly isolated nosocomial
pathogen [4,5]. Nearly all P. aeruginosa clinical cases can be
associated with compromised host defence. Systemic infections are
common in patients with severe burns, and immunosuppressed
AIDS and cancer patients. The infection by P. aeruginosa can also
be seen with contact lenses wearers that develop keratitis of the
cornea. P. aeruginosa is also responsible for ventilator-acquired
peneumonia, and it is the primarily cause of mortality in cystic
fibrosis patients due to lung infection [4]. The pathogenicity of P.
aeruginosa is associated to several virulence factors but ETA is
produced by 95% of P. aeruginosa clinical isolates and it is the most
toxic [6]. It has been reported that ETA deficient strains are less
pathogenic in mice than wild-type strains [7,8], and that the
immunization directed against ETA increased survival in normal
and thermally injured mice infected by P. aeruginosa [9–14]. It is
also clear that ETA contributes to the organism’s pathogenicity in
keratitis [15,16]. Overall, the high incidence of this microorgan-
ism, the severity of its infection and the resistance to antimicrobial
treatments promote P. aeruginosa as a major human pathogen.
The implementation of a vaccine program in the 1940s and
1950s based on diphtheria toxoid had nearly eliminated diphtheria
in developing countries. However, recent outbreaks of diphtheria
have been reported in countries like Russia, in newly independent
states of the former Soviet Union, and in poor socio-economically
disadvantaged groups living in crowded conditions in Europe and
the US [17,18]. One reason for the re-emergence of epidemics in
countries where immunization have been performed has been
explained by a lack of exposure to toxigenic strains of diphtheria
necessary for the boost and maintenance of immunity against this
pathogen [17]. It is well documented that the level of immunity
declines in late childhood and adolescence, and some serological
surveys demonstrated that more than 50% of adults lack immunity
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tion of a new biotype of toxigenic C. diphtheriae could also be a
factor in the re-emergence of diphtheria [17,21]. It is now
admitted that a lack of immunity against diphtheria in adults
represents a potential threat that could lead to the development of
epidemics in industrialized countries [17,21].
The molecular target of DT, ETA and cholix toxin is the
diphthamide residue whose biosynthesis consists of stepwise
modifications of a histidine residue present at position 715 (699
in yeast) [22–27]. Five proteins named Dph1 to Dph5 are involved
in this process in yeast and eukaryotic cells [28–31]. The chemical
transformation into diphthamide requires three successive bio-
chemical reactions starting with the transfer of a 3-amino-3-
carboxypropyl from AdoMet to the imidazole C-2 of the histidine
residue [25]. Studies in yeast and Chinese hamster ovary (CHO)
cells indicated that Dph1 to Dph4 are implicated in the first
biochemical transformation [29–31]. More recently, WDR85
was identified as the fifth protein involved in the first step of
diphthamide formation [32]. In the second step, Dph5 is involved
in the trymethylation of the diphthamide intermediate [28] and,
up to now, no protein involved in the last step of the diphthamide
biosynthesis has been identified. Diphthamide can be found in all
eukaryotic organisms and in archaebacteria except eubacteria,
suggesting a relevant role in cell physiology [33,34]. The
diphthamide residue is located at the tip of a domain loop in
EF2 that mimics the anticodon loop of a tRNA. It has been
suggested that diphthamide stabilizes the tRNA-anticodon-
mRNA-codon interaction and is necessary to maintain the
translation reading frame [35,36]. Nevertheless, except for yeast
Dph3 mutants, the other yeast and CHO cell lines deficient in
some of the Dph genes do not show distinctive phenotypes except
for DT and ETA resistance [27,31,37]. We thus reasoned that
the blockade of diphthamide formation could be an efficient
therapeutic strategy for treating P. aeruginosa or C. diphtheriae
infections.
Dph1 and Dph2 interact in vivo in yeast as well as in eukaryotic
cells, and it has also been suggested that these two proteins could
be part of a catalytic complex involved in the first step of
diphthamide synthesis [31,38]. We then hypothesized that it could
be possible to generate a mutant of Dph1 or Dph2 that could
inhibit in a dominant manner the formation of diphthamide. We
report in this study the identification of a C-terminal deletion
mutant of Dph2 that could completely protect cells against the
toxicity of DT and ETA.
Results
A C-terminal Dph2 Deletion Mutant Protects Cells
Against DT Toxicity
Deletion mutants of Dph2 were generated in order to create a
dominant negative protein that could block the first step of
diphthamide formation. First, the hamster Dph2 cDNA gene was
cloned by PCR amplification using degenerated primers based on
the mouse and the human sequence. A strong homology was
found with the mouse and human Dph2 nucleotide sequence with
89% and 82% identity, respectively. Three deletion mutants were
constructed: a 158 amino acid N-terminal deletion mutant;
Dph2(N-), a 91 amino acid C-terminal deletion mutant;
Dph2(C-), and a 16 amino acid deletion mutant between residues
160–176; Dph2(Z-) (Fig. 1A). The Dph2(Z-) mutant was designed
using the ‘‘PROSITE’’ program that identified a putative leucine
zipper motif between residues 160–181 [39]. These mutants were
then transfected into TE671 cells followed by DT selection. All the
cells transfected with the N- and the Z-deletion mutants were
killed by DT, like the untransfected control cells. On the contrary,
the plate transfected with Dph2(C-) gave rise to a high number of
DT-resistant colonies, indicating that this mutant was able to
protect cells against DT toxicity (Fig. 1B). Similar results were also
obtained with other human cell lines and CHO cells (data not
shown). We are also in the process of defining the shortest deletion
mutant that could confer resistance to DT and ETA: preliminary
results indicate that the same human Dph2 deletion mutant is
functional but not a shorter version with a 133 amino acid deletion
(data not shown).
Cells Expressing Dph2(C-) and Cells Dph2-deficient are
Equally Resistant to DT
In order to investigate to which extent Dph2(C-) could protect
cells against DT, CHO cells expressing Dph2(C-) were cultured
with increasing concentrations of DT up to 10
22 mg/ml. There
was no significant effect on the proliferation of cells expressing
Dph2(C-) even if they were cultured with the highest dose of DT.
These cells were as resistant to DT as RPE.33d that is a
Figure 1. A C-terminal Dph2 deletion mutant protects against
DT toxicity. A, Schematic drawings of Dph2 and Dph2 deletion
mutants. B, Dph2(C-) confers DT resistance in TE671 cells. TE671 cells
untransfected and transfected with plasmids expressing Dph2(C-),
Dph2(N-) and Dph2(Z-) were selected with DT for 7 days. Colonies
were then fixed with methanol and stained with methylene blue. The
colony assay was performed three times; one representative exper-
iment is displayed.
doi:10.1371/journal.pone.0015753.g001
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Wild-type CHO cells were killed with 10
25 mg/ml of DT (Fig. 2).
These data demonstrated a strong potency of Dph2(C-) in
protecting cells against DT toxicity.
Dph2(C-) Confers Resistance to ETA
We next tested the ability of Dph2(C-) to protect against ETA.
Proliferation experiments with increasing ETA concentrations
were performed on CHO cells that had been transfected with
dph2(C-) and selected with DT. These cells were completely
resistant to ETA at concentrations as high as 10
22 mg/ml, while
the viability of parental CHO cells was reduced by 70% with as
little as 10
25 mg/ml of the toxin (Fig. 3). This result indicated that
DT protection conferred by Dph2(C-) could be extended to ETA.
Dph2(C-) Prevents the ADP-ribosylation of EF-2 by DT
The mechanism of toxin protection conferred by Dph2(C-) was
investigated in vitro using an EF-2 ADP-ribosylation assay. Protein
extracts from different CHO cell lines were incubated with DT
and radiolabeled nicotinamide adenine dinucleotide (NAD), and
run in an SDS-PAGE gel. As shown by autoradiography, EF-2
was ADP-ribosylated in parental CHO cells and in CHO cells
transfected with the inactive N- and Z-deletion mutants. However,
no EF-2 ADP-ribosylated form could be detected in CHO cells
expressing Dph2(C-), indicating that the absence of diphthamide
was responsible for the lack of DT toxicity. As expected, EF-2 from
RPE.33d cells could not be ADP-ribosylated but the enzymatic
activity of DT could be detected after transfection of dph2 in those
cells (Fig. 4A). EF-2 was present in similar amounts in all tested
samples as shown by Western blot (Fig. 4B).
Dph2(C-) Binds Dph1 and Competes with Wild-type
Dph2
One possible explanation for the Dph2(C-) anti-toxin activity
was a competition with endogenous Dph2 for the binding to
Dph1, leading to the block of the first biochemical step of
diphthamide formation. Cotransfection/immunoprecipitation ex-
periments showed that Dph2(C-) fused to a TAP-tag could be
immunoprecipitated by an anti-myc antibody recognizing a Dph1-
myc fusion protein (Fig. 5; lane 2). Furthermore, cotransfection of
Dph2-TAP and Dph2(C-) expression plasmids in a 1:1 ratio (Fig. 5;
lane 4) decreased the amount of Dph2-TAP recovered by
immunoprecipitation with the anti-myc antibody (Fig. 5; lane 4
versus lane 3). With a 10-fold excess of the Dph2(C-) plasmid over
the Dph2 plasmid, the band corresponding to Dph2-TAP on the
Western blot was barely detected (Fig. 5; lane 5). These results
clearly showed that Dph2(C-) binds to Dph1, and that it competes
with wild-type Dph2.
Figure 2. CHO cells expressing Dph2(C-) are highly resistant to
DT. DT dose response was measured in a cell proliferation assay. Data
are expressed as a proliferation percentage relative to the proliferation
of cells in the absence of drug. Data are the average of at least four
values 6 s.d. from one representative experiment that was reproduced
twice. Statistical significance was assessed by one-way ANOVA followed
by Dunnett’s multiple comparison posttest. The values of each point in
the curves are compared to those obtained with the 10
28 mg/mlD T
concentration (**, p,0.01; *, p,0.05).
doi:10.1371/journal.pone.0015753.g002
Figure 3. CHO cells expressing Dph2(C-) are resistant to ETA.
ETA dose response was measured in a cell proliferation assay. Data are
expressed as a proliferation percentage relative to the proliferation
of cells in the absence of drug. Data are the average of at least four
values 6 s.d. from one representative experiment that was reproduced
twice. Statistical significance was assessed by one-way ANOVA followed
by Dunnett’s multiple comparison posttest. The values of each point in
the curves are compared to those obtained with the 10
28 mg/ml ETA
concentration (**, p,0.01).
doi:10.1371/journal.pone.0015753.g003
Figure 4. Absence of ADP-rybosylation by DT in CHO cells
expressing Dph2(C-). A, Autoradiography of cellular extracts that
underwent an ADP-rybosylation assay. B, Western blot with an antibody
directed against EF-2. The lane between the CHO lane and the RPE.33d
lane was not relevant and has been deleted. One representative
experiment out of two is displayed.
doi:10.1371/journal.pone.0015753.g004
Resistance to P. Exotoxin A and Diphtheria Toxin
PLoS ONE | www.plosone.org 3 December 2010 | Volume 5 | Issue 12 | e15753Discussion
In addition of being the target of DT and ETA, it is assumed
that the diphthamide residue present on EF-2 plays an important
biological role since it is present in all eukaryotic organisms and in
archaebacteria [33,34]. Nevertheless, CHO cells mutated for
diphthamide formation are able to synthesize proteins and grow as
well as wild-type cells [27,31]. These observations led us to predict
that a strategy that prevents the formation of diphthamide to
confer DT and ETA resistance is likely to be safe. In the present
study, we have designed a dominant-negative strategy that could
prevent diphthamide formation and that could render cells
resistant to DT and ETA toxicity. We found that Dph2(C-), a
C-terminal deletion mutant of Dph2, could completely block DT
and ETA induced toxicity by preventing the ADP-rybosylation of
EF-2. Dph2(C-) was able to bind Dph1 and to compete with wild-
type Dph2, suggesting that the first step of diphthamide formation
was impaired.
All Dph proteins involved in the biosynthesis of diphthamide
have been well studied. Dph1 is a candidate tumor suppressor gene
that has been cloned independently as Ovca1; a loss of Dph1
heterozygosity is frequent in breast and ovarian carcinoma and is
associated to a decrease in protein expression [40]. Ovca1
heterozygote mice develop spontaneous cancer, thus, confirming
the suppressor function of Dph1. Dph1 is also essential to mouse
development as the Ovca1
2/2 mice die during embryonic
development and at birth with developmental delay and defects
in multiple organ systems. Moreover, embryonic fibroblasts from
these mice revealed a role of Dph1 in the regulation of cell
proliferation [40]. The phenotype of Dph4-null mutants is similar
to Ovca1
2/2 mice but heterozygous mice for the Dph4 mutation
do not develop tumors, suggesting an additional tumor suppressive
function for Dph1 [41]. In addition to DT resistance, yeast Dph3
mutants show defect in growth and drug, and temperature
sensitivity suggesting a broader biological role for Dph3 [31,42].
Dph3 knockout mice have also been generated and are associated
with lethality during embryonic life [43]. Dph3 has a role outside
diphthamide formation that could account for the severe
phenotypes observed in knockout mice [44]. It is also most likely
that a Dph2 null mutation in mice would be lethal before or at
birth. The generation of a transgenic mouse with a conditional
expression of Dph2(C-) could circumvent the possible lethality
associated to the absence of the wild-type gene and allow the study
of the role of the diphthamide residue in adult tissue. This mouse
model could be used to assess the efficacy of Dph2(C-) in the
treatment of P. aeruginosa infections.
From a therapeutic stand-point, it would be feasible to deliver
the Dph2(C-) gene directly at sites of P. aeruginosa infection. For
example, viral or non viral delivery systems could be used to
introduce Dph2(C-) in corneal cells as a local treatment for
refractory P. aeruginosa-induced keratitis [45]. A similar gene
therapy strategy could also be offered via aerosol to cystic fibrosis
patients that develop P. aeruginosa infections in the lungs [46] or for
topical treatments of wounds in burn patients [47]. The crystal
structure of a Dph1/Dph2(C-) complex may help in the
development of small molecules with similar therapeutic activity
as Dph2(C-). High-throughput screening technologies with
chemical libraries could also lead to drug candidates for the
treatment of P. aeruginosa and C. diphtheria infection.
Dph2(C-) might also be useful for the treatment of other
pathogenic bacteria. Indeed, cholix toxin from Vibrio cholerae has
the same mechanism of toxicity of DT and ETA [3], and putative
ADP-rybosyltransferases with a diphthamide residue as target
have also been identified in Neisseria gonorrhoeae and Staphilococcus
aureus [48]. Finally, efforts are being made to develop antidotes to
counter the health consequences of bioterrorism; dominant-
negative mutants of anthrax toxin have already been identified
[49], and Dph2(C-) could also be a valuable asset against potential
ETA- or DT-based bioweapons.
In conclusion, our results indicate that it is possible to com-
pletely abolish DT and ETA toxicity by blocking the formation of
diphthamide with a dominant-negative strategy. This is the first
demonstration that the targeting of a cellular component can
protect against DT and ETA toxicity. Dph2(C-) could have a
broad range of clinical applications, including its use alone or in
combination with standard antibiotics for the treatment of P.
aeruginosa and C. diphtheriae infection. This approach is likely to have
a reduced risk of generating resistance, a common outcome with
antibiotic therapy.
Materials and Methods
DNA Constructions
The hamster Dph2 gene was amplified by RT-PCR from CHO-
K1 cells using the mouse 59 primer Dph2E-59 59-ATCGAATT-
CATGGAGTCTACGTTCAGCAG-39 containing a EcoRI site
(underlined) and a 39 degenerated primer designed according to
the mouse and human Dph2 sequence 59-TCAGCNGCTNC-
CCTCATC-39. The pBS-Dph2 plasmid was then obtained by
cloning the PCR product in pBluescript SK+ (Stratagene, La Jolla,
CA) opened in EcoRI/EcoRV. The hamster Dph2 gene was
sequenced and deposited to GenBank (accession no. DQ981502).
Three deletion mutants of Dph2 were constructed by PCR using
pBS-Dph2 as template, and they were cloned in the eukaryotic
vectors pMD2iPuro
r, pcDNA3-TAP and pNC described else-
where [50–52].
For Dph2, a PCR was performed with the following primers:
Dph2K-59 59-CGGGGTACCATGGAGTCTACGTTCAG-39
containing a KpnI site (underlined) and a Dph2B-39 39 primer
59-CGCGGATCCGCCGCTGCCCTCATCCT-39 containing a
BamHI site (underlined). The KpnI/BamHI digested PCR pro-
duct was then cloned in pcDNA3-TAP opened in KpnI/BamHI
to create the pcDNA-Dph2-TAP plasmid.
The C-terminal mutant was constructed by PCR with the 59
primer Dph2K-59 and the 39 primer 59-GAATTCGGGAGTG-
Figure 5. Dph2(C-) binds to Dph1 and competes with wild-type
Dph2. Western blot analysis performed with an anti-TAP antibody of
cellular extracts immunoprecipitated with an anti-myc antibody. Lane 1,
untransfected 293T cells were used as control; lane 2, pcDNA-Dph1-myc
and pNC-Dph2(C-)-TAP plasmids were cotransfected; lane 3–5, pcDNA-
Dph1-myc and pNC-Dph2-TAP plasmids were cotransfected with 0, 1,
and 10 mg of Dph2(C-) plasmid. One representative experiment out of
two is displayed.
doi:10.1371/journal.pone.0015753.g005
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tained by cloning the KpnI digested PCR fragment in pcDNA3-
TAP opened in BamHI blunted by klenow and KpnI.
pNC-Dph2-TAP and pNC-Dph2(C-)-TAP were generated by
cloning in pNC opened in BamHI Dph2-TAP and Dph2(C-)-TAP
linked to a BamHI adaptor.
The pMD2-Dph2iPuro
r was constructed by cloning in pMD2i-
Puro
r opened in EcoRI/XhoI Dph2 from pBS-Dph2 digested by
EcoRI/XhoI.
The pMD2-Dph2(C-)iPuro
r plasmid was constructed by insert-
ing a Dph2(C-) PCR product with the 59 primer Dph2E-59 and
the 39 primer 59-TTAATTCGGGAGTGGAACAT-39 digested
by EcoRI and inserted in pMD2iPuro
r opened by EcoRI/
EcoRV.
For the construction of the N-terminal mutant, the PCR ampli-
fication was performed using the 59 primer 59-CGCGGTACC-
ATGGAGCCAGCTTGTGC-39 containing a KpnI site (under-
lined) and the 39 primer Dph2B-39. The PCR product was
digested by KpnI and BamHI and ligated in the pcDNA3-TAP
plasmid to give the pcDNA-Dph2(N-)-TAP plasmid.
The leucine zipper mutant (Z-) was created using two different
PCR fragments ligated together in pcDNA3-TAP. The first
segment was amplified with the 59 primer Dph2K-59 and the 39
primer 59-GGCATGGGCACAAGCTG-39, and the second frag-
ment was amplified with the 59 primer 59-ATCTCCAGCC-
CAGCTCTT-39 and the 39 primer Dph2B-39. The pcDNA-
Dph2(Z-)TAP plasmid was constructed by cloning the first
amplification product digested by KpnI and the second one
digested by BamHI in pcDNA3-TAP.
The pMD2-Dph2(N-)iPuro
r and pMD2-Dph2(Z-)iPuro
r plas-
mids were constructed similarly. The KpnI/BamHI fragment
from pcDNA-Dph2(N-)-TAP or pcDNA-Dph2(Z-)-TAP was
blunted klenow and ligated in pMD2iPuro
r vector digested by
EcoRV and XbaI blunted by klenow. A stop codon was created at
the C-terminal end due to the cloning procedure.
The mouse Dph1 gene was amplified by RT-PCR using cDNAs
prepared from mouse PG13 cells with the following primers: the
59 primer 59-ATGGCGGCGCTGGTA-39 and the 39 primer
59-CGCGGATCCGGGAGCCGGCGAAGTA-39 containing a
BamHI site (underlined). The PCR product was then digested
by BamHI and ligated in pcDNA3.1(-)/myc-His A (Invitrogen,
Carlsbad, CA) to create the pcDNA-Dph1-myc vector.
Tissue Culture and Transfections
CHO K1 cells (ATCC CCL-61) were grown in RPMI medium
(Invitrogen, Carlsbad, CA), and TE671 (ATCC CRL-8805),
RPE.33d [27], HeLa (ATCC CCL-2) and 293T [53] cells were
cultured in Dulbecco’s modified Eagle’s medium (Sigma, Oakville,
Canada). Both media were supplemented with 10% fetal calf
serum (PAA laboratories, Etobicoke, Canada) and antibiotics.
Transfections of CHO K1 and HeLa cells were performed
either by the calcium phosphate method or using linear Poly-
ethylenimine (PEI; Polysciences, Warrington, PA), whereas the
RPE.33d cells were only transfected with PEI. For the PEI
transfection, 2 mg of PEI per mg of DNA are mixed in 500 mlo f
serum free DMEM for 15 min. The mixture is then added to
subconfluent cells in a 60-mm culture dish containing 5 ml of
DMEM with 10% fetal calf serum. The transfection mixture is
kept overnight until the following day. For the generation of stable
transfectants, CHO K1 and RPE.33d were selected with
puromycin at 10 mg/ml and 5 mg/ml, respectively, and a
concentration of 5610
25 mg/ml was used for the selection of
cells with DT (List Biological laboratories, Campbell, CA).
Cell Proliferation Assay [54]
The cells were plated at a concentration of 3610
3 cells/well in
96-well plates in six replicates for each toxin concentration. The
next day, increasing concentrations of DT or ETA (List Biological
laboratories) were added to the wells for 3 days. Cell proliferation
was then measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) (Sigma) assay, which consists of
adding 37.5 ml of MTT (1 mg/ml) to the 150 ml of medium in
each well for 4 hours at 37uC. After gently removal of the
medium, 150 ml of dimethyl sulfoxide (DMSO) was added and
plates were gently shaken for 10 minutes to dissolve the formazan
blue crystals. The absorbance was then measured at 595 nm with
a microplate reader (Tecan, Research Triangle Park, NC).
ADP-ribosylation Assay
Confluent cells grown in 60-mm plates were lysed in 400 mlo f
modified RIPA buffer (50 mM Tris-HCl, pH 7.4, 1% Nonidet P-
40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA
and protease inhibitors) at 4uC for 45 minutes. Cell extracts were
then centrifuged at 13,0006g for 30 minutes at 4uC, and the
protein concentration of the supernatant was determined by the
Bradford protein assay (Biorad, Hercules, CA). DT was nicked by
mixing together 27 ml of DT (1 mg/ml) with 3 ml trypsin (10 mg/
ml) for 15 minutes. The reaction was stopped by adding 1 mlo f
protein inhibitors (Sigma, P8340). For the ADP-ribosylation assay,
100 mg of protein extract were mixed with 500 ng nicked DT, 2 ml
[C
14]NAD, 288 mCi/mmol (GE Healthcare, Baie d’Urfe, Can-
ada), 20 mM Tris-HCL, pH 7.5, 50 mM dithiothreitol (DTT),
1 mM EDTA at 30uC for 30 minutes in a final volume of 120 ml.
From the 120 ml reaction, 50 ml were mixed with 17 mlo f4 X
sample buffer (200 mM Tris-HCL, 8% SDS, 0.4% bromophenol
blue, 40% glycerol, 400 mM DTT) and analysed by SDS-PAGE
on a 10% acrylamide gel followed by autoradiography.
Immunoprecipitation
293T cells plated in 60-mm plates were transfected with 1 mgo f
the pcDNA-Dph1-myc plasmid with 1 mg of pNC-Dph2-TAP,
and with 0, 1 or 10 mg of pMD2-Dph2(C-) plasmids. One mgo f
the pcDNA-Dph1-myc plasmid with 1 mg of pNC-Dph2(C-)-TAP
were also transfected to assess the binding of Dph2(C-) with Dph1.
Two days post-transfection, cells were lysed in 500 ml of E1A
buffer (20 mM HEPES pH7.9, 250 mM NaCl, 0.1% IGEPAL,
10% glycerol, 1 mM b-mercaptoethanol and protease inhibitors)
at 4uC for 30 minutes. The lysis product was then incubated with
1 mg of the a-myc antibody (clone 9E10) (Sigma) at 4uC for
4 hours. Following this incubation, the extracts were treated with
protein A-Sepharose (GE Healthcare) at 4uC for 1 hour. The
beads were then washed three times with E1A buffer and
ressuspended in 40 ml loading buffer (50 mM Tris-Cl pH6.8, 2%
SDS, 0,1% bromophenol blue, 10% glycerol, 100 mM DTT). The
samples were then analyzed by Western blot.
Western Blot Analysis
Cell extracts prepared for the ADP-ribosylation assays were also
analysed by Western blot. Thirty mg of total protein extract were
mixed with sample buffer (as described above) and loaded on a
10% SDS-polyacrylamide gel and separated by electrophoresis.
The proteins were transferred on nitrocellulose membranes (GE
Healthcare) followed by Western blotting using a goat antibody
directed against a linear peptide of the carboxyl terminus of EF-2
(Santa Cruz Biotechnology, Santa Cruz, CA). For the immuno-
precipitation experiment, the samples were analysed with an anti-
TAP antibody (Open Biosystems, Huntsville, AL). The reactive
Resistance to P. Exotoxin A and Diphtheria Toxin
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cence Reagent Plus kit (Perkin Elmer Life Sciences, Boston, MA).
Statistical Analysis
One-way ANOVA followed by Dunnett’s multiple comparison
posttest was performed with GraphPad Prism (GraphPad Software
Inc., San Diego, CA) on data presented in figures 2 and 3.
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